Latest news with #AdverumBiotechnologies
Business Insider
26-06-2025
- Business
- Business Insider
Mizuho Securities Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report) today and set a price target of $12.00. The company's shares closed today at $2.58. Confident Investing Starts Here: Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Insmed, and Verastem. According to TipRanks, Suvannavejh has an average return of -7.4% and a 40.59% success rate on recommended stocks. Adverum Biotechnologies has an analyst consensus of Strong Buy, with a price target consensus of $17.00. The company has a one-year high of $10.14 and a one-year low of $1.78. Currently, Adverum Biotechnologies has an average volume of 345.4K. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock. Last month, Laurent Fischer, the CEO, PRESIDENT AND DIRECTOR of ADVM sold 9,126.00 shares for a total of $18,252.00.
Yahoo
02-05-2025
- Business
- Yahoo
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.33 per share, equal to the per share closing price of Adverum's common stock as reported by Nasdaq on the grant date of May 1, 2025. The stock options vest over four years, with 25% vesting on the first anniversary of the applicable vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Adverum through the applicable vesting dates. The restricted stock units vest over three years, with one third (1/3rd) vesting on each anniversary of the applicable vesting commencement date, subject to the employee being continuously employed by Adverum through the applicable vesting dates. The awards are subject to the terms and conditions of Adverum's 2017 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit Corporate and Investor Inquiries: Adverum Investor Relations Email: ir@ Media:Jason Awe, Director, Corporate CommunicationsEmail: jawe@ in to access your portfolio
Yahoo
31-03-2025
- Business
- Yahoo
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside chat may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the event. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit Inquiries:Adverum Investor RelationsEmail: ir@ in to access your portfolio
Yahoo
18-02-2025
- Business
- Yahoo
3 US Penny Stocks With Market Caps Below $400M
As major U.S. stock indexes hover near record highs, investors are closely watching market movements and economic indicators for signs of future trends. For those interested in exploring smaller or newer companies, penny stocks—though an outdated term—remain a viable investment area with potential value. These stocks, often characterized by lower price points and the possibility of growth, can be particularly appealing when backed by strong financials and solid fundamentals. In this article, we explore three U.S. penny stocks that exhibit financial strength and may offer promising opportunities for long-term success. Name Share Price Market Cap Financial Health Rating BAB (OTCPK:BABB) $0.88 $6.39M ★★★★★★ QuantaSing Group (NasdaqGM:QSG) $3.08 $127.27M ★★★★★★ ZTEST Electronics (OTCPK:ZTST.F) $0.249 $9.16M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.79 $84.63M ★★★★★★ Permianville Royalty Trust (NYSE:PVL) $1.41 $46.53M ★★★★★★ Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M ★★★★★★ Smith Micro Software (NasdaqCM:SMSI) $1.39 $24.65M ★★★★★☆ PHX Minerals (NYSE:PHX) $4.13 $154.8M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.8718 $78.41M ★★★★★☆ Safe Bulkers (NYSE:SB) $3.59 $383.33M ★★★★☆☆ Click here to see the full list of 705 stocks from our US Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Adverum Biotechnologies, Inc. is a clinical-stage company focused on developing gene therapy product candidates for ocular diseases, with a market cap of $92.78 million. Operations: Adverum Biotechnologies generates revenue from the development and commercialization of gene therapeutics, totaling $1 million. Market Cap: $92.78M Adverum Biotechnologies, with a market cap of US$92.78 million, is pre-revenue and focuses on gene therapy for ocular diseases. Recent data from the LUNA Phase 2 and OPTIC trials show promising results in reducing treatment burdens for wet AMD patients, with significant reductions in anti-VEGF injections and strong patient preference for their Ixo-vec therapy. Despite being unprofitable and forecasted earnings decline, Adverum maintains a solid cash position with no debt, providing a runway of 1.9 years if cash flow trends continue. The company plans to initiate Phase 3 trials in 2025 to further evaluate Ixo-vec's efficacy. Unlock comprehensive insights into our analysis of Adverum Biotechnologies stock in this financial health report. Gain insights into Adverum Biotechnologies' outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases, with a market cap of approximately $281.12 million. Operations: Neumora Therapeutics, Inc. currently does not report any revenue segments as it is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases and related disorders. Market Cap: $281.12M Neumora Therapeutics, with a market cap of US$281.12 million, is pre-revenue and focused on treatments for brain diseases. Despite being debt-free and having short-term assets exceeding liabilities, the company faces challenges with increased losses over five years and heightened stock volatility. Recent management changes include Paul L. Berns transitioning to CEO amid executive reshuffles. Legal issues arise from a class action lawsuit related to their IPO disclosures. The KOASTAL-1 Phase 3 study for navacaprant in major depressive disorder showed no significant improvement on primary endpoints but demonstrated safety without serious adverse events reported. Navigate through the intricacies of Neumora Therapeutics with our comprehensive balance sheet health report here. Examine Neumora Therapeutics' earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Nerdy, Inc. operates a platform for live online learning and has a market cap of approximately $351.74 million. Operations: The company's revenue is primarily derived from its Educational Services segment, specifically in Education & Training Services, which generated $197.33 million. Market Cap: $351.74M Nerdy, Inc., with a market cap of US$351.74 million, has faced challenges due to its unprofitability and increased losses over the past five years. Despite this, the company remains debt-free and has sufficient cash runway for more than three years based on current free cash flow. Nerdy recently regained compliance with NYSE listing standards after addressing share price concerns. A significant development is its partnership with Clover School District through Varsity Tutors for Schools, enhancing educational resource access for students nationwide. The management team and board are experienced but face volatility in stock performance amidst broader industry challenges. Click here to discover the nuances of Nerdy with our detailed analytical financial health report. Explore Nerdy's analyst forecasts in our growth report. Explore the 705 names from our US Penny Stocks screener here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:ADVM NasdaqGS:NMRA and NYSE:NRDY. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
